NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
NICE’s 2025 Guidance on Obesity Management Support
NICE HealthTech Methods Update